background: cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (nsclc). many novel drugs, including gemcitabine, vinorelbine, paclitaxel and docetaxel have been used in combination with cisplatin in this setting. of these drugs, gemcitabine is reported to have a high response rate and acceptable toxicity. the aim of this study was to evaluate the effi...

Background: Boron neutron capture therapy (BNCT) is a radiotherapy that combines biological targeting and high linear energy transfer. A potential therapeutic approach for non-small cell lung cancer (NSCLC) is considered. However, dose in lung tumor is not homogeneous, and it will reduce the effect of BNCT treatment. In order to improve the dose distribution of BNCT, the multi-field irradiation...

background: boron neutron capture therapy (bnct) is a radiotherapy that combines biological targeting and high linear energy transfer. a potential therapeutic approach for non-small cell lung cancer (nsclc) is considered. however, dose in lung tumor is not homogeneous, and it will reduce the effect of bnct treatment. in order to improve the dose distribution of bnct, the multi-field irradiation...

given the unmet needs in cancer treatment, extensive research and development has evolved to offer therapies for cancers to extend survival and minimize side effects. immunotherapy, an approach to harness normal immune cells against cancers not only today’s breakthrough but in fact the future of oncology therapeutics. taking into consideration the recent approvals for new lines of therapy inclu...

Updates to the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) 2021 include recommendations biomarker testing in all appropriate patients with newly diagnosed advanced lung cancer, including squamous cell cancer. When a targetable genetic alteration is detected, recommend treatment first-line therapy targeted that alteration. The guidelines contain new information on use of adjuvant osim...

Previous studies show inconsistent effect estimates for the efficacy of Endostar in patients with advanced non-small cell lung cancer (NSCLC) undergoing chemoradiotherapy. Therefore, this meta-analysis aimed to determine the effectiveness and safety on the basis of data obtained from available randomized controlled trials (RTCs). We find relevant articles reporting the use of Endostar combined ...

The role of interleukin 6 (IL-6) in regulating the growth of three human non-small cell lung carcinoma (NSCLC) cell lines (NSCLC-3, NSCLC-5, and NSCLC-7, derived from a primary lesion, a brain lesion, and lymph node metastases, respectively) was examined. Although IL-6 alone did not alter the growth of these cells, the addition of soluble IL-6 receptor (sIL-6R) led to the inhibition of prolifer...

Background: To determine which radiotherapy parameters are associated with the tumor response of locally advanced non-small cell lung cancer (NSCLC) patients undergoing concurrent chemoradiotherapy. Materials and Methods: Thirty one patients with IIIA/IIIB NSCLC underwent chemoradiotherapy with a median dose of 63 Gy. On our actual treatments, we made radiotherapy planning to cover the planning...